WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573339
Description: Ilepatril, also known as AVE-7688, is a vasopeptidase inhibitor for the treatment of hypertension.
MedKoo Cat#: 573339
Chemical Formula: C22H28N2O5S
Exact Mass: 432.1719
Molecular Weight: 432.54
Elemental Analysis: C, 61.09; H, 6.53; N, 6.48; O, 18.49; S, 7.41
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: AVE-7688, Ilepatril
IUPAC/Chemical Name: (4S,7S,12bR)-7-((S)-2-(acetylthio)-3-methylbutanamido)-6-oxo-1,2,3,4,6,7,8,12b-octahydrobenzo[c]pyrido[1,2-a]azepine-4-carboxylic acid
InChi Key: FXKFFTMLFPWYFH-RDGPPVDQSA-N
InChi Code: 1S/C22H28N2O5S/c1-12(2)19(30-13(3)25)20(26)23-16-11-14-7-4-5-8-15(14)17-9-6-10-18(22(28)29)24(17)21(16)27/h4-5,7-8,12,16-19H,6,9-11H2,1-3H3,(H,23,26)(H,28,29)/t16-,17+,18-,19-/m0/s1
SMILES Code: [H][C@@]1(C2=CC=CC=C2C[C@@H]3NC([C@@H](SC(C)=O)C(C)C)=O)N([C@H](C(O)=O)CCC1)C3=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 432.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Davidson EP, Coppey LJ, Yorek MA. Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment. Invest Ophthalmol Vis Sci. 2012 Dec 7;53(13):8067-74. doi: 10.1167/iovs.12-10826. PubMed PMID: 23169880; PubMed Central PMCID: PMC3517272.
2: Davidson EP, Coppey LJ, Holmes A, Dake B, Yorek MA. Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications. Eur J Pharmacol. 2011 Oct 15;668(3):497-506. doi: 10.1016/j.ejphar.2011.07.016. Epub 2011 Jul 28. PubMed PMID: 21816138; PubMed Central PMCID: PMC3185159.
3: Coppey L, Davidson E, Lu B, Gerard C, Yorek M. Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice. Neuropharmacology. 2011 Feb-Mar;60(2-3):259-66. doi: 10.1016/j.neuropharm.2010.09.008. Epub 2010 Sep 16. PubMed PMID: 20849865; PubMed Central PMCID: PMC3014404.
4: Tabrizchi R. Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9. Review. PubMed PMID: 18311667.